瑞舒伐他汀与依折麦布联合治疗冠心病急性心肌梗死的疗效观察

Therapeutic effect of rosuvastatin combined with ezetimibe on acute myocardial infarction in patients with coronary heart disease

目的探讨瑞舒伐他汀与依折麦布联合治疗冠心病急性心肌梗死的疗效。方法选择2016年1月—2017年12月某医院收治的冠心病急性心肌梗死患者102例,以随机数表法将其分为对照组与研究组,每组各51例。对照组采用依折麦布片治疗,研究组在此基础上应用瑞舒伐他汀片治疗。结果研究组治疗的总有效率为92.16%,高于对照组70.59%(P<0.05)。治疗后研究组左室舒张末期容积(Left Ventricular End-diastolic Volume,LVEDV)低于对照组(P<0.05),左心室射血分数(Left ventricular ejection fraction LVEF)高于对照组(P<0.05)。两组治疗期间均未见明显的药物不良反应。结论冠心病急性心肌梗死患者应用瑞舒伐他汀联合依折麦布治疗效果显著,值得临床推广。

Objective To investigate the therapeutic efficacy of rosuvastatin combined with ezetimibe in the treatment of acute myocardial infarction in patients with coronary heart disease.Methods A total of 102 coronary heart disease patients with acute myocardial infarction were selected in a hospital from January 2016 to December 2017 and they were divided into a control group and a trial group by the random number table method,with 51 cases in each group.The control group was treated with ezetimibe tablets,and the trial group was treated with rosuvastatin combined with ezetimibe.Results The total effective rate of the trial group was 92.16%,which was higher than that of the control group(70.59%)(P<0.05).After the treatment,the left ventricular end-diastolic volume(LVEDV)of the trial group was lower than that of the control group(P<0.05),and the left ventricular ejection fraction(LVEF)of the trial group was higher than that of the control group.There were no obvious adverse drug reactions during the treatment in both groups.Conclusion The effect of rosuvastatin combined with ezetimibe on acute myocardial infarction in patients with coronary heart disease is remarkable,which is worthy of clinical promotion.